> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Charles River Raises 2026 Profit Outlook To $11.35-$11.55 A Share As Organic Growth Hits 4.7%
- URL: https://www.bullished.co/charles-river-raises-2026-profit-outlook-to-11-35-11-55-a-share-as-organic-growth-hits-4-7-1d332405/
- Published: 2026-11-04T12:26:03.000Z
- Updated: 2026-11-04T12:26:03.000Z
- Description: The drug-testing company lifted its adjusted EPS and organic revenue guidance; a foreign tax reversal inflated reported earnings to $6.86 a share.
- Author: Matteo Parrino
- Tags: Earnings, CRL, Industry: Healthcare

Charles River Laboratories, which supplies research animals, testing services and quality-control products to drug developers, raised its 2026 guidance after third-quarter organic revenue [rose 4.7%](https://www.sec.gov/Archives/edgar/data/0001100682/000110068226000156/crl3q26earningsrelease.htm?ref=bullished.co), ahead of the company's own prior outlook. Adjusted earnings per share now are guided to $11.35 to $11.55, from $11.15 to $11.45, the company said Wednesday.

## Growth returns, margins widen

Third-quarter revenue was $982.7 million, down 2.2% from $1,004.9 million a year earlier, mostly because of the May 2026 divestitures. Stripping out acquisitions, divestitures and currency, organic revenue grew 4.7%, the company's second straight quarter of organic growth.

Adjusted earnings were $3.09 per share, up 27.2% from $2.43\. The adjusted operating margin rose 330 basis points (3.3 percentage points) to 23.0%, which the company attributed to the sale of its CDMO (contract manufacturing) business and higher volume in safety assessment services. A lower tax rate also helped.

CEO Birgit Girshick said revenue and earnings outperformed prior expectations and that DSA net bookings and proposals "continued to show robust, year-over-year increases."

## A $5.06 tax benefit inflates reported EPS

Standard accounting earnings were $6.86 per diluted share, against $1.10 a year earlier. That figure includes a $245.6 million benefit, or $5.06 per share, from reversing acquired tax reserves after newly enacted tax legislation and completion of certain tax requirements in a foreign jurisdiction.

The reversal also lifted the reported operating margin 730 basis points to 20.6%, via a $44.6 million benefit in the Discovery and Safety Assessment segment.

## Segments and the new guidance

Discovery and Safety Assessment, the outsourced drug discovery and regulatory safety testing unit, had revenue of $596.3 million, down 0.7%, with organic growth of 5.9% on higher regulated safety study volume. Manufacturing Solutions, which supplies microbial and biologics testing, grew organically 7.4%, the fastest of the three, though reported revenue fell 6.2% to $178.9 million on the CDMO sale. Research Models and Services, the rodent-breeding unit, saw organic revenue slip 0.6% to $207.5 million reported, down 2.8%.

For the full year, organic revenue growth is now guided to at least 1.5%, from 0.0% to 1.0%. Reported revenue is guided to fall 2.0% to 1.5%, from a 3.5% to 2.5% decline. Standard-accounting EPS guidance is $8.15 to $8.35, from $3.05 to $3.35\. The company said the increase mainly reflects the third-quarter outperformance in DSA and the lower tax rate.

Management hosted a webcast at 9:00 a.m. ET on Wednesday to discuss the quarter.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)](https://www.sec.gov/Archives/edgar/data/0001100682/000110068226000156/crl-20261104.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit crl3q26earningsrelease.htm — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001100682/000110068226000156/crl3q26earningsrelease.htm?ref=bullished.co) — SEC EDGAR